DMAC NASDAQ
Credit Risk of going bust: lower than 90% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), DiaMedica Therapeutics Inc. would be worth roughly what it owes.
Total debt $185K against a stock market value of $471.3M.
Distance to default 13.95 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $150K (short-term plus half of long-term), stock volatility 56.9%; Altman Z'' -8.04. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Minneapolis, MN 55305
US
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Pauls Dietrich John | A-Award | 60,200 | — | 2026-08-10 |
| Parsons James T. | A-Award | 10,095 | $8.42 | 2026-01-02 |
| Giuffre Randall Mich | A-Award | 6,175 | $8.42 | 2026-01-02 |
| Semba Charles Paulin | A-Award | 3,355 | $8.42 | 2026-01-02 |
| STAHLBERG JAN | P-Purchase | 73,099 | $8.57 | 2025-11-25 |